Published in Health and Medicine Week, August 2nd, 2004
DNABarrier II is one of three applications currently under development using the dSLIM immunomodulator technology, developed and patented by Mologen. Following signature of a detailed term sheet, a first installment of 0.4 Mill Euro was received by Mologen.
This licensing deal is for Mologen the first financially important outcome from strategic alliances with biopharmaceutical companies and investors in China.
The license embraces the use of DNABarrier II in treatments of several major cancers,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health and Medicine Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.